{
  "kind": "treatment",
  "slug": "naltrexone-bupropion-contrave",
  "type": "weight-management",
  "name": "Naltrexone-Bupropion (Contrave)",
  "summary": "A combination medication used for chronic weight management in adults with obesity or overweight with weight-related comorbidities.",
  "description": "Naltrexone-bupropion is an extended-release combination of an opioid antagonist (naltrexone) and a norepinephrine-dopamine reuptake inhibitor (bupropion). It is used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. The combination targets both appetite regulation and reward pathways involved in eating behavior.",
  "category": "medications/weight-management",
  "tags": [
    "weight loss",
    "appetite suppressant",
    "obesity treatment"
  ],
  "metadata": {
    "drug_classes": [
      "Opioid Antagonist",
      "Norepinephrine-Dopamine Reuptake Inhibitor"
    ],
    "therapeutic_categories": [
      "Weight Management",
      "Metabolic Health"
    ],
    "mechanism_categories": [
      "Dopamine Blocker"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": false,
    "brand_names": [
      "Contrave"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "X",
    "age_groups": [
      "Adult"
    ],
    "treatment_duration": [
      "Long-term"
    ],
    "specialty_areas": [
      "Endocrinology",
      "Primary Care",
      "Bariatric Medicine"
    ],
    "fda_approval_year": 2014
  },
  "clinical_metadata": {
    "primary_indications": [
      "Other"
    ],
    "off_label_uses": [
      "None well established"
    ],
    "contraindications": [
      "Uncontrolled hypertension",
      "Seizure disorders",
      "Chronic opioid use or acute opioid withdrawal",
      "Eating disorders (anorexia, bulimia)",
      "Use of other bupropion-containing products",
      "MAOI use within 14 days"
    ],
    "monitoring_required": [
      "Blood pressure",
      "Heart rate",
      "Neuropsychiatric symptoms",
      "Weight and BMI"
    ],
    "efficacy_rating": {
      "weight_loss": 4
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "naltrexone bupropion",
      "contrave",
      "weight loss medication",
      "obesity treatment"
    ],
    "synonyms": [
      "naltrexone hydrochloride and bupropion hydrochloride ER"
    ],
    "common_misspellings": [
      "naltrexon",
      "buproprion",
      "contrav"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Chronic weight management in adults with BMI ≥30 kg/m²",
        "Chronic weight management in adults with BMI ≥27 kg/m² with at least one weight-related condition (e.g., hypertension, type 2 diabetes, dyslipidemia)"
      ]
    },
    {
      "type": "mechanism",
      "text": "Bupropion enhances activity of norepinephrine and dopamine, reducing appetite and cravings; naltrexone blocks opioid receptors, modulating reward pathways involved in eating."
    },
    {
      "type": "dosing",
      "adult": {
        "titration": "Week 1: 1 tablet AM; Week 2: 1 tablet AM, 1 tablet PM; Week 3: 2 tablets AM, 1 tablet PM; Week 4 and onward: 2 tablets AM, 2 tablets PM",
        "tablet_strength": "8 mg naltrexone / 90 mg bupropion per tablet"
      },
      "hepatic_impairment": "Moderate: 1 tablet AM and 1 tablet PM; Severe: Not recommended",
      "renal_impairment": "Moderate to severe: Max 1 tablet AM and 1 tablet PM"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Extended-release tablets: 8 mg naltrexone / 90 mg bupropion"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Weight loss effects may be observed within 4–8 weeks; evaluate efficacy at 12 weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "nausea",
        "constipation",
        "headache",
        "vomiting",
        "dizziness",
        "insomnia",
        "dry mouth"
      ],
      "less_common": [
        "increased blood pressure",
        "anxiety",
        "tremor"
      ],
      "serious": [
        "seizures",
        "suicidal thoughts and behaviors",
        "hepatotoxicity",
        "angle-closure glaucoma"
      ]
    },
    {
      "type": "warnings",
      "black_box": "Bupropion component may increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults.",
      "other": [
        "Risk of seizure increases with higher doses",
        "Can cause elevated blood pressure and heart rate"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "MAOIs",
          "risk": "Hypertensive crisis",
          "action": "Contraindicated; 14-day washout"
        },
        {
          "with": "Opioids",
          "risk": "Precipitated withdrawal, reduced analgesia",
          "action": "Contraindicated"
        },
        {
          "with": "Drugs that lower seizure threshold",
          "risk": "Increased seizure risk",
          "action": "Use caution"
        },
        {
          "with": "CYP2B6 inhibitors",
          "risk": "Increased bupropion levels",
          "action": "Monitor and adjust dose"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Blood pressure and heart rate at baseline and periodically",
        "Weight and BMI",
        "Neuropsychiatric symptoms",
        "Signs of hepatotoxicity"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Category X; contraindicated",
      "lactation": "Avoid during breastfeeding",
      "pediatrics": "Not established; contraindicated under 18",
      "geriatrics": "Monitor for hypertension and neuropsychiatric effects"
    },
    {
      "type": "clinical_notes",
      "items": [
        "Discontinue if <5% weight loss after 12 weeks at maintenance dose",
        "Encourage concurrent lifestyle modifications for best results",
        "Not for use in opioid-dependent patients"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Contrave Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "AACE/ACE Obesity Guidelines",
          "url": "https://www.aace.com/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Naltrexone-Bupropion (Contrave): Weight Management Guide",
    "description": "Evidence-based information on naltrexone-bupropion (Contrave) for chronic weight management, including dosing, side effects, and safety."
  }
}
